Thinking Flexibly in Biomanufacturing
Single-use systems may offer a suitably flexible solution to the biomanufacturing challenges of cost and time-to-market.
The global biopharmaceutical market is set to grow by a compound annual growth rate of nearly 14% over the next six years, according to market research. Reported drivers for this progression include an aging global population, an increase in the prevalence of chronic conditions, and an overall rise in the uptake of biopharmaceutical products on the global market.
In this article, the benefits, evolution, and limitations of single-use systems in biomanufacturing are explored.
Read this article in BioPharm International's Single-Use Systems 2019 eBook.
Article Details
BioPharm International
eBook: Single-Use Systems 2019
June 2019
Pages: 4–8
Citation
When referring to this article, please cite it as F. Thomas, "Thinking Flexibly in Biomanufacturing," BioPharm International's Single-Use Systems eBook (June 2019).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
